News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) To Present At Upcoming Investor Forums In New York



2/27/2014 8:01:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, “the Company”) will present a corporate overview and provide an update of its CVac™ development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time).

At the time of the presentation, a live webcast of Prima's presentation will be available at the following link: www.visualwebcaster.com/event.asp?id=98054.

After the presentation, an archived version of the webcast will be available on Prima’s website at www.primabiomed.com.au.

About Prima BioMed

Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cellbased product currently in clinical trials. www.primabiomed.com.au

About the Wall Street Analyst Forum Institutional Investor Conference

Since 1989, The Wall Street Analyst Forum has sponsored over 80 analyst conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston & London. Over 2,200 different public corporations have presented and analysts & portfolio managers from over 2000 different institutions have attended in person & via webcast.

For further information please contact:

USA Investor/Media:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au

Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au

Europe Investor/Media:
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES